Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. News
  7. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Genmab A/S : HC Wainwright Downgrades Genmab to Neutral From Buy

08/24/2021 | 08:36am EDT


© MT Newswires 2021
All news about GENMAB A/S
10/21PRESS RELEASE : Pfizer and BioNTech Announce Phase -3-
DJ
10/20Lower rates mean climate costs higher than thought, SF Fed paper says
RE
10/20JOHNSON & JOHNSON : Genmab Announces Net Sales of DARZALEX (daratumumab) for the Third Qua..
AQ
10/19GENMAB A/S : Company Announcement - Form 6-K
PU
10/19GENMAB A/S : Darzalex Sales Hit $1.58 Billion In Q3
MT
10/19GENMAB A/S : Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GL
10/19Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GL
10/19Genmab A/S Announced DARZALEX Sales Results for the Third Quarter of 2021
CI
10/18GENMAB A/S : has published its Articles of Association
AQ
10/18GENMAB A/S : Janssen Receive Positive Opinion for Lung Cancer Treatment from EU Committee
MT
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Financials
Sales 2021 8 090 M 1 267 M 1 267 M
Net income 2021 2 394 M 375 M 375 M
Net cash 2021 14 751 M 2 310 M 2 310 M
P/E ratio 2021 85,2x
Yield 2021 -
Capitalization 196 B 30 583 M 30 625 M
EV / Sales 2021 22,4x
EV / Sales 2022 16,6x
Nbr of Employees 1 029
Free-Float 94,9%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | GMAB | DK0010272202 | MarketScreener
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 2 991,00 DKK
Average target price 2 804,30 DKK
Spread / Average Target -6,24%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S21.44%30 583
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610